July 2021

The cumulative annual sales exceeded 10 million yuan, and the financing of nearly 100 million yuan was completed

June 2021

The GMP manufacturing platform was successfully certified by the ISO9001 and IS013485 quality management systems

April 2021

3D TableTrix^® Cell Microcarrier Tablet obtained the qualifications DMF for pharmaceutical excipients from the US FDA (DMF:35481)

February 2021

3D TableTrix^® Cell Microcarrier Tablet obtained two qualifications for pharmaceutical excipients from CDE (Filing No.:F20200000496/F20210000003)

December 2020

3D TableTrix^® microcarrier core products were released in United States, the European Union, Japan and other countries

October 2020

3D FIoTrix^@ VS series of pilot-scale production-grade bioreactors were officially released in the market

June 2020

Proprietary products of 3D TableTrix^® series of microcarrier tablet officially were officially released in the market

January 2020

The certification of intellectual property management system was completed

December 2019

The application for "Zhongguancun Subversive Project" was successful; the certification of "National High-tech Enterprise" was obtained and the company ranked among top 3 in "Global Entrepreneurship World Cup" at the same time

October 2019

followed by A GMP-certified manufacturing base of 2000 square meters launched in the next month.

March 2019

In March 2019, Cytoniche received angel fund and a R&D center of 1500 square meters was therefore launched.

2018

In 2018, the technology was successfully translated into Beijing CytoNiche Biotechnology Co., Ltd., joined by Tsinghua University equity-wise.

After more than 10 years of research in the field of cell microcarriers, Professor Du Yanan of Tsinghua University along with his research team have published a number of international leading research achievements internationally